Utrecht spinout developing FOXO4-derived senolytic peptides to selectively destroy senescent cells in cancer and chronic disease.
San Francisco biotech developing drugs that activate iNKT immune cells to clear senescent cells from the body.
Including Funding rounds + valuations, Founders + executives, Products + tech stack, Headcount + HQ, Status timeline, and Roster connections.
Already subscribed? Sign in →